Aktienanalyse zu Entrada Therapeutics Inc (TRDA)TRDAEntrada Therapeutics Inc

Entrada Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in establishing a class of medicines, which engages intracellular targets. Its Endosomal Escape Vehicle (EEV)-therapeutics are designed to enable the delivery of a range of therapeutics into a variety of organs and tissues, resulting in an improved therapeutic index. The Company is advancing a robust development portfolio of genetic medicines for the potential treatment of neuromuscular and inherited retinal diseases, among others. The Company is focused on the development of EEV therapeutics for rare neuromuscular diseases, including Duchenne muscular dystrophy (DMD) and myotonic dystrophy type 1 (DM1). It has partnered to develop a clinical-stage program, VX-670, for myotonic dystrophy type 1. The Company has advanced two ocular programs into lead optimization for the potential treatment of inherited retinal diseases. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

Entrada Therapeutics Inc is currently not a strong buy due to its high net losses and declining collaboration revenue, despite a recent narrower loss of $42.76 million in Q2 2026. The current price is $7, which is significantly lower than the analyst price target of $11, indicating potential upside. However, the RSI is at 40.012, suggesting it is nearing oversold territory, but the negative trend in insider selling (up 1842.13%) raises concerns about confidence in the stock.